Abstract Number: 1676 • ACR Convergence 2023
Tofacitinib Accelerates in Vitro Clot Formation and Delays Clot Lysis in Rheumatoid Arthritis Blood by Enhancement of Macrophage TLR4 Mediated Cytokine Responses- a New Angle on Thrombosis with JAKi in Rheumatology
Background/Purpose: Rheumatoid Arthritis (RA) patients treated with Janus Kinase inhibitors (JAKi) have reportedly higher venous thromboembolism (VTE) risk and atherosclerotic-related complications including myocardial infarction (1).Although…Abstract Number: 1769 • ACR Convergence 2023
TNF-Stimulated Production of IL-15 by Fibroblast-Like Synoviocytes Mediates Human Resident Memory T Cells Development in Synovial Organoid Model
Background/Purpose: Rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) are chronic autoimmune diseases that tend to flare repeatedly in the same joints, displaying joint-specific memory.…Abstract Number: 2149 • ACR Convergence 2023
Biologic IRL201805 Drives Differential Cell-contact and Metabolism Transcriptional Profiles in Monocytes from RA Patients Compared to Healthy Donors
Background/Purpose: IRL201805 is a novel biologic derived from Binding Immunoglobulin Protein (BiP) that has been developed for the treatment of Rheumatoid arthritis (RA) (P Eggleton,…Abstract Number: 2552 • ACR Convergence 2023
Inflammatory Fibrosis Precedes Loss of Kidney Function in Lupus Nephritis
Background/Purpose: Interstitial fibrosis in lupus nephritis (LN) is often infiltrated by immune cells. However, this is typically regarded as nonspecific "scar reaction" rather than active…Abstract Number: 0095 • ACR Convergence 2023
Kynurenine Is a Proinflammatory Metabolite That Activates a Positive Feedback Loop of Rab4A-dependent CD98 Expression and mTORC1 and mTORC2 Activation in SLE
Background/Purpose: The kynurenine (KYN) pathway has been linked to disease pathogenesis in patients with systemic lupus erythematosus (SLE) (https://pubmed.ncbi.nlm.nih.gov/26366134/). Genetically enforced overexpression of Rab4A activates…Abstract Number: 0525 • ACR Convergence 2023
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Background/Purpose: In patients (pts) with axial spondyloarthritis (axSpA), tumor necrosis factor inhibitors (TNFi) are the usual first line biologic treatment, yet many pts may experience…Abstract Number: 0884 • ACR Convergence 2023
Identification of a Mast Cell-high Synovial Pathotype of Osteoarthritis
Background/Purpose: Mast cells in the osteoarthritis (OA) synovium correlate with disease severity. This study aimed to further elucidate the role of mast cells in OA…Abstract Number: 1147 • ACR Convergence 2023
Blood-Based Biomarkers of Inflammation and Tissue Remodeling Can Discriminate Between Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis and Are Associated with Hand Function
Background/Purpose: Inflammatory musculoskeletal diseases including rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are characterized by physical function impairment due to progressive inflammatory and structural changes.…Abstract Number: 1711 • ACR Convergence 2023
CD14+ Monocytes Demonstrate a Unique Transcriptional Signature in Macrophage Activation Syndrome, Highlighting a Role for Interferons and Identifying Putative Hemophagocytes in Circulation
Background/Purpose: Macrophage activation syndrome (MAS) is a potentially fatal complication of rheumatic diseases. MAS is characterized by a dysfunctional hyperinflammatory response in which there is…Abstract Number: 1776 • ACR Convergence 2023
Macrophage Migration Inhibitory Factor May Help Maintain Tight Junctions in the Gut by Enhancing Occludin Expression
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory disease with multifactorial origins, primarily affecting the musculoskeletal system. Gut inflammation is seen in the majority of…Abstract Number: 2157 • ACR Convergence 2023
Exploratory Analysis of the Mechanisms of Action of the Potential Analgesic Effect of Tofacitinib and Adalimumab over Placebo in Patients with Rheumatoid Arthritis: Results of a Mediation Modeling Analysis
Background/Purpose: Pain is the most common symptom reported by patients (pts) with rheumatic disorders, such as RA.1 Improvement in pain with antirheumatic drugs is generally…Abstract Number: 2557 • ACR Convergence 2023
Clinicopathologic Features of Patients with Giant Cell Arteritis and Thoracic Aorta Repair: A Single Center Experience over Two Decades
Background/Purpose: Patients with giant cell arteritis (GCA) are at increased risk of thoracic aortic aneurysm and dissection. This late complication of the disease is presumed…Abstract Number: 0149 • ACR Convergence 2023
Impacts of Social Determinants of Health and the Immune System in Adults with Acute-to-Chronic Low Back Pain: An Observational Study
Background/Purpose: Chronic low back pain (cLBP) is common worldwide yet poorly understood due to the combination of biological, psychological, and sociological factors. An individual's social…Abstract Number: 0553 • ACR Convergence 2023
Serum Isolevuglandin IgG Antibody Concentrations Are Increased in Patients with Systemic Lupus Erythematosus versus Control Subjects and Associated with Lower 24-hour Blood Pressure
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a 2-3-fold increased risk of cardiovascular events. A major risk factor for this is hypertension. We previously…Abstract Number: 0913 • ACR Convergence 2023
Neutrophils in Patients with Systemic Lupus Erythematosus Show Pronounced Inflammatory Signals
Background/Purpose: IFN response, plasmablasts and neutrophils are three hallmarks of systemic lupus erythematosus (SLE). Studies showed that the netting neutrophils stimulated plasmacytoid dendritic cells to…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 67
- Next Page »